18,960 independent pharmacies are still standing. The software keeping them there is more consolidated than they are.

An independent pharmacy runs on fewer than five real vendors — dispensing system, point-of-sale, adherence dialer, PBM reconciliation, and (if applicable) a 340B contract-pharmacy platform. Three of those five now sit under two corporate parents. The pharmacy count is shrinking; the vendor count is shrinking faster. Buyer leverage is thinner than the count of logos suggests.

18,960 pharmacies in a $103B market with 10-year low gross profits

The NCPA 2025 Digest released October 19, 2025 put the count at 18,960 independent pharmacies as of July 2025, down slightly from 18,984 the prior June. That's roughly 36% of all US retail pharmacies and a $103 billion market — with the same year showing a 10-year high in cost of goods, a 10-year high in average annual sales, and a 10-year low in gross profits. The compression is real, and it changes what an independent should ask of a software vendor. The old sourcing question was “does this platform have the features I want.” The 2026 question is “does this platform give me leverage on the parts of the P&L that are actually moving” — meaning cash-cycle length, PBM reconciliation recovery, immunization throughput per staff hour, and audit posture on 340B claims. Features don't fix a 10-year low in gross profit; workflow speed and recovery accuracy might.

Two corporate parents hold most of the independent pharmacy stack

RedSail Technologies is the umbrella over PioneerRx, BestRx, QS/1, Emporos, Axys, TransactRx, and PowerLine — a portfolio that spans dispensing systems (PioneerRx, BestRx, QS/1), long-term-care pharmacy (Axys, PowerLine), point-of-sale (Emporos), and switching/claim transactions (TransactRx). On the reconciliation and clinical-services side, FDS Amplicare — historically the leading adherence dialer plus PBM-reconciliation stack — was combined into Omnicell's EnlivenHealth division, placing it alongside Omnicell's automation and central-fill hardware business. What's left outside those two parents is a meaningful but narrower field: Liberty Software, Datascan, McKesson EnterpriseRx, plus specialty 340B platforms like Kalderos, IntegriChain, and 340B ESP. An operator running PioneerRx on the dispensing side and EnlivenHealth on the reconciliation side is buying from RedSail and Omnicell. That's not a knock on either — it's a note that when the same corporate parent holds the dispensing platform and the POS, the price of leaving either is higher.

Buyer-side. Supplier-paid. Buyers pay zero. Compensation has zero weight in the Cardinal Index scoring inside the Cardinal Method. Specific commercial terms live only in the private Decision Memo a buyer signs, never on this page.

DIR reform on January 1, 2024 landed as a cash-flow shock, not a policy change

CMS's final rule required Medicare Part D price concessions to be included at the point of sale beginning January 1, 2024 — replacing the previous model, where DIR fees were assessed retroactively months after the fill. The Epstein Becker Green summary lays out the mechanism: pharmacies now see the lowest possible reimbursement at fill time, but the transition period created severe cash-flow compression through H1 2024 because pharmacies were still paying 2023 retroactive DIR while collecting reduced 2024 reimbursements. Two years later, independents without dedicated PBM reconciliation tooling are still finding uncaptured recoveries — either DIR assessments that were duplicated across the transition or point-of-sale concessions that didn't match the contracted formulary. The vendor screen: what does the last 90 days of DIR assessment look like at point-of-sale, and what would it have looked like retroactively under the old model. If the vendor can't produce that report, the pharmacy can't see what it's losing.

340B contract-pharmacy claims live or die on NCPDP field 420-DK

Contract-pharmacy arrangements between covered entities and independent pharmacies are dispensed against the covered entity's 340B account, and the claim has to be identified as such. The mechanism is Submission Clarification Code (SCC) “20” in NCPDP field 420-DK, per Frier Levitt's summary of the identification and submission requirements. Mis-identification in either direction is expensive: missing the code on a 340B fill exposes the covered entity to HRSA audit findings; applying it when the drug isn't 340B invites manufacturer recoupment demands. Meanwhile, 2026 has continued the manufacturer restrictions on contract-pharmacy arrangements, which means the reconciliation tooling has to keep pace with which manufacturers still ship and under what conditions. If the dispensing platform doesn't route the SCC flag correctly at claim submission, the whole downstream reconciliation is compromised. Ask the vendor to demo it — not just describe it.

The 5-item vendor screen

1. Which corporate parent owns our dispensing platform, our POS, our adherence dialer, and our reconciliation tool — and where are we double-paying inside the same parent?
2. Show us the last 90 days of DIR fee assessments at point-of-sale, side by side with what would have been retroactive under the pre-2024 model.
3. If we add 340B contract pharmacy, show us the NCPDP SCC “20” submission-clarification workflow and the audit-ready claims-identification report.
4. What's our real cash-cycle length: date of dispense → date of remit — and where is the biggest single delay?
5. Show us the immunization scheduling flow from patient text through claim submission — one screen or five.

Sources

• NCPA, “NCPA Releases 2025 Digest Report” (October 19, 2025). ncpa.org
• Cardinal Health, “2025 NCPA Digest: State of the industry” (distribution partner's mirror of the Digest data). cardinalhealth.com
• RedSail Technologies, “Our Brands” portfolio page (PioneerRx, BestRx, QS/1, Emporos, Axys, TransactRx, PowerLine). redsailtechnologies.com
• EnlivenHealth, press release on the FDS Amplicare combination. enlivenhealth.co
• Epstein Becker Green, “CMS Finalizes Changes to Pharmacy DIR in Part D Starting with Contract Year 2024.” ebglaw.com
• Frier Levitt, “340B Claims Identification and Submission Requirements” (NCPDP SCC “20” in field 420-DK). frierlevitt.com
• 340B Report, “Navigating Contract Pharmacy Restrictions in 2026.” 340breport.com

All linked sources were live at time of publish (July 2026). Verify before quoting in a procurement document.